{'fraction_non_alphanumeric': 0.025, 'fraction_numerical': 0.006896551724137931, 'mean_word_length': 5.7894736842105265, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Expert opinions on clinical application of interferon-γ release assay of Mycobacterium tuberculosis (2021 edition)].

Interferon-γ release assay (IGRA) is an in vitro immunological technique for Mycobacterium tuberculosis diagnosis, which is recommended by the World Health Organization. As one of the auxiliary diagnosis methods for active tuberculosis in diagnostic criteria of China, the method and technique have been developed in recent years, and a wealth of clinical applied experience has been accumulated in the clinical application in China. Based on the "Opinions of applications of IGRA in China (2014 edition)" issued by Chinese Society for Tuberculosis, Chinese Medical Association, it was revised and improved according to the latest developments and clinical experience, and the expert opinions were presented in six parts: principles and technical advances, quality control, application of latent tuberculosis infection diagnosis, auxiliary diagnosis of active tuberculosis, application in special populations, and the influence of common drugs on IGRA results, with a view to providing guidance for the clinical application of IGRA in China.